Literature DB >> 26170957

Expression of survivin in adenoid cystic carcinoma of the lacrimal gland and the effect of intervention with arsenic trioxide in vitro.

Yingzhe Pan1, Yiqiao Xing2, Hui Wang1.   

Abstract

The aim of the present study was to investigate the role of survivin in adenoid cystic carcinoma of the lacrimal gland (LGACC) and the effect of arsenic trioxide (As2O3) intervention in vitro. In total, 13 patients with LGACC were recruited from Renmin Hospital of Wuhan University between 2007 and 2012. The patients were divided into different groups, namely tumor-node-metastasis (TNM)1-2 and TNM3-4, according to the TNM classification. A total of eight samples were included in the TNM1-2 group, while five samples were included in the TNM3-4 group. In addition, six patients that suffered from other diseases (no tumor), but underwent eye surgery, were selected as the controls. The mRNA and protein expression levels of survivin were analyzed. In addition, primary adenoid cystic carcinoma (ACC) cells were cultured and the expression of survivin was silenced using short interfering RNA (siRNA), after which the cell proliferation was determined. Furthermore, the primary cultured ACC cells were treated with different doses of As2O3 to observe the effect on the apoptosis rate. The mRNA and protein expression levels of survivin in the LGACC groups were higher when compared with the controls (P<0.01). In addition, the expression levels were higher in the TNM3-4 group when compared with the TNM1-2 group (P<0.01). After silencing survivin expression using siRNA, the rate of ACC cell proliferation was shown to decrease at days 2, 3, 4 and 5 following culture, particularly in the TNM3-4 group at days 2 and 3 (P<0.05), day 4 (P<0.01 vs. TNM1-2 + siRNA); and days 3 and 5 (P<0.05), and day 2 (P<0.01 vs. TNM3-4 + siRNA). The mRNA expression levels of survivin in the TNM1-2 and TNM3-4 groups were significantly decreased following treatment with the various doses of As2O3 (2, 4 and 6 µΜ) for 48 h, and the apoptosis rate of the ACC cells was markedly increased (TNM1-2 and 3-4: As2O3 6 µM vs. As2O3 2 µM, As2O3 6 µM vs. As2O3 4 Μm, P<0.01; TNF3-4, As2O3 4 µM VS. As2O3 2 µM, P<0.01; TNM1-2, As2O3 4 µM vs. As2O3 2 µM, P<0.05). Therefore, survivin was demonstrated to be highly expressed in ACC cells of the lacrimal gland, and inhibition of survivin gene expression was found to suppress the proliferation of the ACC cells. Furthermore, As2O3 treatment was demonstrated to inhibit the mRNA expression of survivin in the ACC cells, while significantly increasing the apoptosis rate.

Entities:  

Keywords:  adenoid cystic carcinoma; arsenic trioxide; lacrimal gland; survivin

Year:  2015        PMID: 26170957      PMCID: PMC4487053          DOI: 10.3892/etm.2015.2466

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  17 in total

1.  Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway.

Authors:  Asra Mirza; Marnie McGuirk; Tish N Hockenberry; Qun Wu; Hena Ashar; Stuart Black; Shu Fen Wen; Luquan Wang; Paul Kirschmeier; W Robert Bishop; Loretta L Nielsen; Cecil B Pickett; Suxing Liu
Journal:  Oncogene       Date:  2002-04-18       Impact factor: 9.867

2.  Cell division and cell survival in the absence of survivin.

Authors:  Dun Yang; Alana Welm; J Michael Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-11       Impact factor: 11.205

Review 3.  Role of the apoptotic and mitotic regulator survivin in melanoma.

Authors:  Jodi A McKenzie; Douglas Grossman
Journal:  Anticancer Res       Date:  2012-02       Impact factor: 2.480

4.  Epithelial tumors of the lacrimal gland in the Chinese: a clinicopathologic study of 298 patients.

Authors:  Jie Zeng; Ji-tong Shi; Bin Li; Xian-li Sun; Yu-zhi An; Liao-qing Li; Fei Gao; Jian-ping Xu; Jost B Jonas
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-03-31       Impact factor: 3.117

Review 5.  Targeting survivin in cancer: patent review.

Authors:  Jagat R Kanwar; Sishir K Kamalapuram; Rupinder K Kanwar
Journal:  Expert Opin Ther Pat       Date:  2010-12       Impact factor: 6.674

6.  Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation.

Authors:  C Adida; P L Crotty; J McGrath; D Berrebi; J Diebold; D C Altieri
Journal:  Am J Pathol       Date:  1998-01       Impact factor: 4.307

Review 7.  Survivin, cancer networks and pathway-directed drug discovery.

Authors:  Dario C Altieri
Journal:  Nat Rev Cancer       Date:  2008-01       Impact factor: 60.716

8.  IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs.

Authors:  I Tamm; Y Wang; E Sausville; D A Scudiero; N Vigna; T Oltersdorf; J C Reed
Journal:  Cancer Res       Date:  1998-12-01       Impact factor: 12.701

Review 9.  Adenoid cystic carcinoma of the head and neck--a 20 years experience.

Authors:  H Kokemueller; A Eckardt; P Brachvogel; J-E Hausamen
Journal:  Int J Oral Maxillofac Surg       Date:  2004-01       Impact factor: 2.789

10.  Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells.

Authors:  C H Yang; M L Kuo; J C Chen; Y C Chen
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

View more
  1 in total

1.  MicroRNA-140-5p inhibits salivary adenoid cystic carcinoma progression and metastasis via targeting survivin.

Authors:  Zhu Qiao; Yue Zou; Hu Zhao
Journal:  Cancer Cell Int       Date:  2019-11-16       Impact factor: 5.722

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.